Marcy l'Étoile, October 18, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2018.
Business review for the nine months ended September 30, 2018
Media Statement: bioMérieux commitments in the CDC’s “AMR Challenge”, a joint public-private sector initiative to accelerate the fight against antimicrobial resistance
bioMérieux, a world leader in the field of in vitro diagnostics, is participating in the AMR Challenge, a new Centers for Disease Control and Prevention (CDC) initiative to bring government, healthcare and industry leaders together in a year-long concentrated effort to accelerate the fight against the public health threat of antimicrobial resistance (AMR).
ALERT: Hurricane Florence - Shipping & Order Update
Due to the impact of Hurricane Florence on the east coast, delivery services by national carriers have been interrupted.
bioMérieux – First-Half 2018 Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 4 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2018. The statements had been reviewed by the Statutory Auditors.
Labor Day Shipping Schedule
bioMérieux, Inc. sites in Durham, St. Louis, Louisville and Lombard will be closed on Monday, September 3, in observance of the upcoming holiday.
Independence Day Shipping Schedule
bioMérieux Inc. sites in Durham, St. Louis, Louisville and Lombard will be closed on Wednesday, July 4, in observance of the Independence Day holiday.
Memorial Day Shipping Schedule
bioMérieux Inc. sites in Durham, St. Louis, Louisville and Lombard will be closed on Monday, May 28 in observance of Memorial Day.
bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical
bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers.
Lord Jim O’Neill joins bioMérieux in a knowledge exchange on the challenge of antimicrobial resistance
Marcy l'Etoile, France, March 7, 2017 - bioMérieux, a world leader in infectious disease diagnostics, committed to the fight against antimicrobial resistance (AMR), organized today a panel discussion with Lord Jim O’Neill, an influential economist, politician and philanthropist who chaired the Review on Antimicrobial Resistance.